Endocyte Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Endocyte (ECYT) Misses Q3 EPS by 20c
November 6, 2017 4:02 PM ESTEndocyte (NASDAQ: ECYT) reported Q3 EPS of ($0.55), $0.20 worse than the analyst estimate of ($0.35).
Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte The University of... More